| Bioactivity | ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH)[1]. |
| Target | EC50: 143 nM (FXR). IC50: 2.7 μM (FABP1). |
| Invitro | ZLY28 具有合适的肝微粒体稳定性，对 FXR（EC50 = 143 nM）和 FABP1（IC50 = 2.7 μM）具有高靶向选择性[1]. |
| In Vivo | ZLY28 (oral; 20 mg/kg) 通过调节 NASH 小鼠模型中的脂质代谢、炎症、氧化应激和纤维化等多种发病机制显着缓解脂肪肝[1]。 Animal Model: |
| Name | ZLY28 |
| Formula | C29H23Cl2NO4 |
| Molar Mass | 520.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ren Q, et al. Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease. J Med Chem. 2023;66(9):6082-6104. |